Thus, new strategies for combination therapies, including priming immune responses by neoantigen vaccines, increasing the infiltration of T cells by CpG, and modulating the immunosuppressive environment by anti-CD38 mAb, were all required to achieve an effective anti-tumor response against immunologically cold LLC1 tumors in our model. The gene discussed is CD38; the disease is neoplasm.